Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06445959
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-05-31
Brief Title:
Phase 1b2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-11-29
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-31
First Submit QC Date:
May 31 2024
Study First Post Date:
2024-06-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-04
Last Update Post Date:
2024-06-27
Last Update Post Date Type:
ACTUAL